Framingham and National Cholesterol Education Program tools do not accurately predict coronary heart disease
FORMA Therapeutics has announced that it has entered into a license and option agreement through the Novartis Option Fund. Under the terms of the agreement, FORMA will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology. The agreement includes an upfront fee and
Full Post: FORMA Therapeutics to collaborate with Novartis on inhibitors
The Framingham and National Cholesterol Education Program tools, NCEP, do not accurately predict coronary heart disease, according to a study performed at the Yale University School of Medicine in New Haven, CT.
The study included 1,653 patients who had no history of coronary heart disease; although 738 patients were taking statins (cholesterol lowering drugs like Lipitor) because of increased risk of developing coronary heart disease. All 1,653 patients underwent a coronary CT angiogram and doctors compared their risk of coronary heart disease, determined by the Framingham and NCEP risk assessment tools, to the amount of plaque actually found in their arteries as a result of the scan. Results showed that 21% of the patients who were thought to need statin drugs before the scan (because of the Framingham and NCEP assessment tools) did not require them; “26% of the patients who were already taking statins (because of the risk factor assessment tools) had no detectable plaque at all,” said Kevin M. Johnson, MD, lead author of the study.
“Risk assessment tools are used by physicians implicitly. Physicians use them as a way to separate and treat patients accordingly. Ultimately, the Framingham influences what every physician does, but I feel it is not good enough to show what is happening with each individual patient,” said Dr. Johnson.
“The average person tends to put a lot of weight on family history, but the association between that and coronary heart disease is only modest,” said Dr. Johnson. “We are living in an era where genetic research is in the headlines, but reality is a lot more complicated than that,” he said.
“There are still 400,000 people a year who die from heart attacks and have no warning signs at all; doctors want to be able to find those people before that happens and I hope this study gets people interested in finding out better predictors for coronary heart disease,” said Dr. Johnson.
A study performed by the team of Dr. Nabil G. Seidah, Director of the Biochemical Neuroendocrinology Research Unit at the IRCM, shows for the very first time that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol (LDL-cholesterol) from the bloodstream, may be inhibited by a third protein,
Full Post: Major discovery in the control of bad cholesterol
A Michigan State University researcher is studying whether the most popular class of cholesterol-lowering drugs may cause muscle problems in users. There is accumulating evidence that the effect statins can have on skeletal muscle - including muscle weakness, fatigue and deterioration - is underestimated, said Jill Slade, assistant professor of radiology and osteopathic manipulative medicine
Full Post: Do statins cause muscle problems?
Naturally produced sex hormones may influence the risk and progression of atherosclerosis, or hardening of the arteries, Johns Hopkins researchers report in a recent study. The findings may help explain the increased risk men have of developing heart disease, which runs about twofold higher than women’s heart disease risk worldwide. The study suggests that older
Full Post: Sex hormones may affect atherosclerosis
Even younger adults who have few short-term risk factors for heart disease may have a higher risk of developing heart disease over their lifetimes, according to new findings by a UT Southwestern Medical Center researcher. The findings, based on clinical studies and appearing in the Jan. 19 issue of the journal Circulation: Journal of the
Full Post: Researchers find that healthy, younger adults could be at risk for heart disease
This year, about 450,000 Americans will die of coronary heart disease - the leading cause of death for both men and women. Although we have made great strides in preventing and treating heart disease, we continue to explore the complex mechanisms involved in cardiovascular disease, and we are eager to refine risk assessment tools and
Full Post: Simple blood test for high-sensitivity C-reactive protein is a useful marker for cardiovascular disease